FENC
- Fennec Pharmaceuticals Inc.
()
Overview
Company Summary
Fennec Pharmaceuticals Inc. is a biopharmaceutical company that is focused on developing and commercializing innovative solutions to treat hearing loss. Their primary goal is to address the unmet medical needs of patients who experience hearing loss as a result of certain chemotherapy treatments.
Fennec's lead product candidate, PEDMARK, is a unique formulation of a chemotherapy agent called sodium thiosulfate. It is specifically developed to minimize the toxic effects of certain platinum-based chemotherapy drugs, such as cisplatin, on the inner ear. These drugs can cause hearing loss, known as ototoxicity, which can have a significant impact on a patient's quality of life.
By administering PEDMARK immediately after chemotherapy treatments, Fennec aims to protect and preserve hearing function, particularly in pediatric patients who are highly susceptible to ototoxicity. They believe that with their innovative approach, they can significantly reduce the occurrence and severity of hearing loss in this vulnerable patient population.
Fennec Pharmaceuticals Inc. conducts clinical trials, regulatory activities, and manufacturing efforts to progress PEDMARK through various stages of development. They collaborate with healthcare providers, researchers, and regulatory authorities to bring this potential treatment for chemotherapy-induced hearing loss to market.
In summary, Fennec Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing PEDMARK, a drug designed to prevent and treat chemotherapy-induced hearing loss, with a focus on pediatric patients.